Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Accumulated Expenses (2016 - 2021)

Sunshine Biopharma (SBFM) has disclosed Accumulated Expenses for 8 consecutive years, with $48287.0 as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Accumulated Expenses rose 213.71% year-over-year to $48287.0, compared with a TTM value of $48287.0 through Dec 2021, up 213.71%, and an annual FY2021 reading of $48287.0, up 213.71% over the prior year.
  • Accumulated Expenses was $48287.0 for Q4 2021 at Sunshine Biopharma, down from $84945.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $84945.0 in Q3 2021 and bottomed at $1171.0 in Q1 2017.
  • Average Accumulated Expenses over 5 years is $29464.0, with a median of $28407.5 recorded in 2018.
  • The sharpest move saw Accumulated Expenses soared 1772.25% in 2018, then decreased 29.85% in 2020.
  • Year by year, Accumulated Expenses stood at $9215.0 in 2017, then rose by 0.82% to $9291.0 in 2018, then surged by 66.92% to $15509.0 in 2019, then decreased by 0.75% to $15392.0 in 2020, then surged by 213.71% to $48287.0 in 2021.
  • Business Quant data shows Accumulated Expenses for SBFM at $48287.0 in Q4 2021, $84945.0 in Q3 2021, and $58712.0 in Q2 2021.